Role and development of GLP-1 receptor agonists in the management of diabetes
Chee W Chia, Josephine M EganNational Institutes of Health, National Institute on Aging, Intramural Research Program, Baltimore, Maryland, USAAbstract: Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L cells of the intestine in response to food. Exogenous GLP-...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/557b3719c76d42cf8151d5df75f42c68 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:557b3719c76d42cf8151d5df75f42c68 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:557b3719c76d42cf8151d5df75f42c682021-12-02T05:39:14ZRole and development of GLP-1 receptor agonists in the management of diabetes1178-7007https://doaj.org/article/557b3719c76d42cf8151d5df75f42c682009-05-01T00:00:00Zhttp://www.dovepress.com/role-and-development-of-glp-1-receptor-agonists-in-the-management-of-d-a3139https://doaj.org/toc/1178-7007Chee W Chia, Josephine M EganNational Institutes of Health, National Institute on Aging, Intramural Research Program, Baltimore, Maryland, USAAbstract: Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L cells of the intestine in response to food. Exogenous GLP-1 administration at pharmacological doses results in many effects that are beneficial for treating type 2 diabetes, these include: (1) an increase in insulin secretion from β cells; (2) a suppression of glucagon secretion from α cells in the presence of hyperglycemia but not hypoglycemia; (3) a delay in gastric emptying and gut motility which in turns delays absorption of ingested nutrients and dampens post-prandial glucose excursion; and (4) an increase in the duration of postprandial satiety therefore suppressing appetite and decreasing food intake which eventually leads to weight loss. However, GLP-1 is subject to rapid enzymatic degradation, and therefore, not suitable for long-term treatment. A synthetic enzyme-resistant GLP-1 receptor agonist that reproduces the biological effects of GLP-1 is in use and more are under development. This review aims at providing a summary of the properties of GLP-1 and the development of GLP-1-based therapies for treatment of diabetes.Keywords: incretin, GLP-1, GLP-1R agonist, diabetes Chee W ChiaJosephine M EganDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2009, Iss default, Pp 37-49 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Chee W Chia Josephine M Egan Role and development of GLP-1 receptor agonists in the management of diabetes |
| description |
Chee W Chia, Josephine M EganNational Institutes of Health, National Institute on Aging, Intramural Research Program, Baltimore, Maryland, USAAbstract: Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L cells of the intestine in response to food. Exogenous GLP-1 administration at pharmacological doses results in many effects that are beneficial for treating type 2 diabetes, these include: (1) an increase in insulin secretion from β cells; (2) a suppression of glucagon secretion from α cells in the presence of hyperglycemia but not hypoglycemia; (3) a delay in gastric emptying and gut motility which in turns delays absorption of ingested nutrients and dampens post-prandial glucose excursion; and (4) an increase in the duration of postprandial satiety therefore suppressing appetite and decreasing food intake which eventually leads to weight loss. However, GLP-1 is subject to rapid enzymatic degradation, and therefore, not suitable for long-term treatment. A synthetic enzyme-resistant GLP-1 receptor agonist that reproduces the biological effects of GLP-1 is in use and more are under development. This review aims at providing a summary of the properties of GLP-1 and the development of GLP-1-based therapies for treatment of diabetes.Keywords: incretin, GLP-1, GLP-1R agonist, diabetes |
| format |
article |
| author |
Chee W Chia Josephine M Egan |
| author_facet |
Chee W Chia Josephine M Egan |
| author_sort |
Chee W Chia |
| title |
Role and development of GLP-1 receptor agonists in the management of diabetes |
| title_short |
Role and development of GLP-1 receptor agonists in the management of diabetes |
| title_full |
Role and development of GLP-1 receptor agonists in the management of diabetes |
| title_fullStr |
Role and development of GLP-1 receptor agonists in the management of diabetes |
| title_full_unstemmed |
Role and development of GLP-1 receptor agonists in the management of diabetes |
| title_sort |
role and development of glp-1 receptor agonists in the management of diabetes |
| publisher |
Dove Medical Press |
| publishDate |
2009 |
| url |
https://doaj.org/article/557b3719c76d42cf8151d5df75f42c68 |
| work_keys_str_mv |
AT cheeampnbspwchia roleanddevelopmentofglp1receptoragonistsinthemanagementofdiabetes AT josephinemegan roleanddevelopmentofglp1receptoragonistsinthemanagementofdiabetes |
| _version_ |
1718400296963538944 |